The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus poses serious threats to the global public health and leads to worldwide crisis. No effective drug or vaccine is readily available. The viral RNA-dependent RNA polymerase (RdRp) is a promising therapeutic target. A hybrid drug screening procedure was proposed and applied to identify potential drug candidates targeting RdRp from 1906 approved drugs. Among the four selected market available drug candidates, Pralatrexate and Azithromycin were confirmed to effectively inhibit SARS-CoV-2 replication in vitro with EC 50 values of 0.008μM and 9.453 μM, respectively. For the first time, our study discovered that Pralatrexate is able to potently inhibit SARS-CoV-2 replication with a stronger inhibitory activity than Remdesivir within the same experimental conditions. The paper demonstrates the feasibility of fast and accurate anti-viral drug screening for inhibitors of SARS-CoV-2 and provides potential therapeutic agents against COVID-19. Author summary Currently, a novel coronavirus called SARS-COV-2 is spreading across many parts of the world. Unfortunately, there is still a lack of effective drugs against the virus. Additionally, it usually takes much longer time to develop a new drug using traditional methods. Thus, it is now better to rely on some alternative methods to develop drugs that can treat such a disease effectively. In this paper, we have proposed a deep learning and molecular dynamics simulation based hybrid drug screening procedure for identifying potential drug candidates targeting RdRp from 1906 market available drugs. Our screening have successfully identified a FDA-approved drug called Pralatrexate that strongly inhibits the replication of 2019-nCoV in vitro with EC50 values of 0.008μM. This work demonstrated the feasibility of accurate virtual drug screening for inhibitors of SARS-CoV-2 and provides potential therapeutic agents against COVID-19.
【초록키워드】 COVID-19, SARS-CoV-2, Vaccine, coronavirus, Azithromycin, deep learning, feasibility, threat, 2019-nCoV, drugs, Remdesivir, Drug screening, drug, molecular dynamics, in vitro, severe acute respiratory syndrome Coronavirus, virus, inhibitors, approved drugs, Molecular dynamics simulation, Novel coronavirus, effective drugs, Replication, Spread, Viral, RdRP, RNA-dependent RNA polymerase, therapeutic agents, Viral RNA, respiratory, disease, SARS-CoV-2 replication, anti-viral drug, therapeutic target, leads, Pralatrexate, alternative methods, alternative method, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, viral RNA-dependent RNA polymerase, drug candidates, EC50 values, FDA-approved drug, global public health, inhibitors of SARS-CoV-2, No effective drug, paper, potential therapeutic agents, traditional methods, worldwide crisis, treat, inhibitory activity, screening procedure, selected, identify, lack, develop, inhibit, applied, provide, demonstrated, potential therapeutic agent, conditions, drug candidates targeting, EC50 value, effective drug, hybrid drug, inhibit SARS-CoV-2, 【제목키워드】 Virtual screening, in vitro, Viral, viral replication, RdRP, inhibitor, SARS-CoV-2 RdRp, identify, reduce,